Table 1.
Demographics, disease characteristics and medications.
| N (%) | Mean (SD) or Median (Range) |
|
|---|---|---|
| Gender | ||
| Male | 11 (21%) | |
| Female | 41 (79%) | |
| Mean age (SD)# | 15.9 (2.1) | |
| Race/Ethnicity | ||
| Caucasian | 26 (50%) | |
| Asian | 12 (23%) | |
| Latino | 4 (8%) | |
| African American | 3 (6%) | |
| Other/Unknown | 7 (13%) | |
| Diagnosis | ||
| Juvenile Idiopathic Arthritis | 23 (44%) | |
| Oligoarthritis | 1 (2%) | |
| Rheumatoid factor positive polyarthritis | 3 (6%) | |
| Rheumatoid factor negative polyarthritis | 8 (15%) | |
| Systemic arthritis | 8 (15%) | |
| Enthesitis-related arthritis | 2 (4%) | |
| Psoriatic arthritis | 1 (2%) | |
| Systemic Lupus Erythematosus | 18 (35%) | |
| Juvenile Dermatomyositis | 4 (8%) | |
| Mixed Connective Tissue Disease | 3 (6%) | |
| Scleroderma | 2 (4%) | |
| Idiopathic Thrombocytopenic Purpura | 1 (2%) | |
| Periodic Fever Syndrome | 1 (2%) | |
| Median Disease Duration (Range)# | 5.3 (0-15) | |
| Mean Self-Reported Disease Activity (SD)* | 4.1 (2.6) | |
| Medications | ||
| Corticosteroids | 30 (58%) | |
| Methotrexate or Leflunomide | 24 (45%) | |
| Hydroxychloroquine | 19 (37%) | |
| Biologic | 15 (29%) | |
| Immunosuppressant+ | 13 (25%) | |
| Intravenous Immunoglobulin | 2 (4%) | |
| Non-Steroidal Anti-Inflammatory Drug | 2 (4%) |
# Years.
* Disease activity reported on a 0-10 Likert scale, with 0 meaning "Not Active" and 10 meaning "Very Active."
+ Immunosuppressants include cyclophosphamide, azathioprine, myophenolate mofetil, tacrolimus, and cyclosporine.